Answer:
Regeneron and mAb114
Explanation:
The Ebola virus disease is a harmful viral hemorrhagic disease caused by ebolaviruses, which have a high risk of death (approximately 20% to 90%). In December 2019, the U.S. Food and Drug Administration (FDA) approved Ervebo, which is the first vaccine approved by the FDA with the aim to prevent the Ebola virus disease. Nowadays, there is no antiviral treatment approved by the FDA for patients with Ebola; however, there are two antiviral drug treatments named regeneron (REGN-EB3) and mAb114, which have shown good efficacy to treat the Evola virus. Currently, both antiviral drugs are being used in patients with Ebola.